A study in the Swedish Malmo Preventive Medicine Program (MPMP) found that men with low testosterone were more likely to develop rheumatoid arthritis. The study participants included 33,000 people born between 1921 and 1949. As part of the study, the participants underwent a number of tests, filled out questionnaires, and provided blood samples.
In the study, low testosterone levels are observed in both men and women with rheumatoid arthritis (RA). Further study is required to determine whether low testosterone levels are to blame for the onset of RA, or it is RA that drops the levels of testosterone. Continue reading
Would you like to provide input to inform CADTH’s report and CDEC’s advice?
The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.
CADTH is interested in learning:
- How should fracture risk be best described?
- Is there a place for age (>75 years) or bone density scores, or are these adequately captured within fracture risk?
- How should bisphosphonate failure be best described?
- How should bisphosphonate intolerance be best described?
Advice is sought regarding the alignment of the CDEC recommendations for women (2011) and for men (2015). Continue reading
BC PharmaCare is looking for your input on denosumab (Prolia®) for the treatment of osteoporosis in men
Denosumab (Prolia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide direct feedback about denosumab for the treatment of osteoporosis in men.
You can give input if you are a male B.C. resident living with osteoporosis, a caregiver to someone with osteoporosis, or if your group represents people who live with osteoporosis.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links: Continue reading